Harvard Bioscience(HBIO) - 2025 Q2 - Quarterly Report
2025-08-12 04:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 84 October Hill Road, Holliston, Massachusetts 01746 (Address of Principal Executive Offices, including zip code) ☐ Transi ...
Energy Services of America (ESOA) - 2025 Q3 - Quarterly Results
2025-08-12 04:30
Exhibit 99.1 Energy Services of America Reports Fiscal Third Quarter 2025 Results HUNTINGTON, W.Va., August 11, 2025 /PRNewswire/ -- Energy Services of America Corporation (the "Company" or "Energy Services") (Nasdaq: ESOA), today announced its results for its fiscal third quarter ended June 30, 2025. Third Quarter Summary All comparisons are versus the comparable prior year period, unless otherwise stated. "Our third quarter results show a significant sequential improvement as we entered the more favorable ...
Aris Water Solutions(ARIS) - 2025 Q2 - Quarterly Results
2025-08-12 04:30
Exhibit 10.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED WATER GATHERING AND DISPOSAL AGREEMENT WHEREAS, effective June 11, 2020, the Parties entered into an Amended and Restated Water Gathering and Disposal Agreement and effective as of February 15, 2024, Producer and Gatherer amended such agreement (the "Agreement"); and WHEREAS, the Parties desire to extend the Primary Term of the Agreement by seven (7) years. NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein co ...
Viant(DSP) - 2025 Q2 - Quarterly Results
2025-08-12 04:30
收入和利润(同比环比) - 公司第二季度收入同比增长18%,达到7785.3万美元,毛利润同比增长17%,达到3588.3万美元[2] - 公司净收入同比增长20%,达到178.7万美元,非GAAP净收入同比增长11%,达到801.2万美元[2] - 2025年第二季度收入为7.785亿美元,同比增长18.2%(2024年同期为6.587亿美元)[17] - 2025年上半年收入为14.849亿美元,同比增长24.5%(2024年同期为11.926亿美元)[17] - 2025年第二季度净收入为290万美元,同比增长427.3%(2024年同期为55万美元)[17] - 2025年上半年净亏损为900万美元,同比扩大0.9%(2024年同期为892万美元)[17] - 2025年第二季度收入为7.7853亿美元,同比增长18.2%[33] - 2025年上半年收入为14.8495亿美元,同比增长24.5%[33] - 2025年第二季度非GAAP净利润为8012万美元,同比增长11.2%[37] - 2025年上半年非GAAP净利润为1.0801亿美元,同比增长26.3%[37] - 2025年第二季度GAAP净收入为178.7万美元,非GAAP调整后净收入增至801.2万美元[39] - 2024年第二季度GAAP净收入为148.8万美元,非GAAP调整后净收入增至720.7万美元[39] - 2025年上半年净亏损为15.2亿美元,2024年同期为17.26亿美元[41] - 2025年上半年非GAAP净收入为10.801亿美元,2024年同期为8.555亿美元[41] 成本和费用(同比环比) - 2025年第二季度运营费用为7.784亿美元,同比增长16.8%(2024年同期为6.664亿美元)[17] - 2025年上半年研发支出为1460.2万美元,同比增长32.2%(2024年同期为1104.7万美元)[17] - 2025年上半年股票薪酬支出为1198.2万美元,同比增长20.1%(2024年同期为997.7万美元)[17] - 2025年第二季度股票薪酬支出为6343万美元,同比增长14.5%[35] - 2025年第二季度流量获取成本(TAC)为2.9481亿美元,同比增长21.3%[34] - 2025年上半年折旧和摊销费用为8883万美元,同比增长6.9%[35] - 2025年第二季度股票薪酬调整增加634.3万美元,占非GAAP调整的主要部分[39] - 2024年第二季度股票薪酬调整增加553.7万美元[39] - 2025年第二季度交易费用调整增加36.9万美元[39] - 2024年第二季度重组费用调整增加28.4万美元[39] - 2025年上半年股票薪酬调整增加11.982亿美元,2024年同期为9.977亿美元[41] - 2025年上半年交易费用调整增加667万美元,2024年同期为384万美元[41] - 2025年上半年TRA重新计量费用调整增加325万美元,2024年同期无此项调整[41][42] - 2025年上半年非GAAP税前收入(损失)调整减少653万美元,2024年同期减少547万美元[41][42] 业务线表现 - 公司CTV广告支出创纪录,占总广告支出的45%[1][3] - 公司建立了超过2.5亿美元的潜在年度广告支出机会管道,涉及美国主要广告商[3] 现金流和资本管理 - 公司现金及现金等价物截至6月30日为1.728亿美元[2] - 公司回购了380万股A类普通股,总金额为5020万美元,其中2850万美元为2025年至今回购金额[3] - 截至2025年6月30日,现金及现金等价物为1.728亿美元,同比下降15.7%(2024年12月31日为2.050亿美元)[19] - 2025年上半年经营活动现金流为1.648亿美元,同比下降9.5%(2024年同期为1.821亿美元)[21] - 2025年上半年股票回购支出为2811.7万美元,同比增长433.4%(2024年同期为526.7万美元)[21] 管理层讨论和指引 - 公司预计第三季度收入在8350万至8650万美元之间,贡献收入(Contribution ex-TAC)在5100万至5300万美元之间[11] - 公司预计第三季度调整后EBITDA在1400万至1500万美元之间[11] 其他财务数据 - 公司第二季度贡献收入(Contribution ex-TAC)同比增长16%,达到4837.2万美元,调整后EBITDA同比增长18%,达到1128.3万美元[2] - 2025年第二季度调整后EBITDA为1.1283亿美元,占贡献ex-TAC的23%[35][37] - 2025年上半年调整后EBITDA为1.6685亿美元,占贡献ex-TAC的18%[35][37] - 2025年第二季度贡献ex-TAC为4.8372亿美元,同比增长16.4%[33][37] - 2025年第二季度非控股权益调整后净收入为640.7万美元[39] - 2024年第二季度非控股权益调整后净收入为594.2万美元[39] - 2025年第二季度稀释后每股收益为0.09美元,基本每股收益为0.10美元[39] - 2024年第二季度稀释后每股收益为0.08美元,基本每股收益为0.08美元[39] - 2025年上半年归属于Viant Technology Inc.的基本每股收益为0.14美元,2024年同期为0.09美元[41] - 2025年上半年稀释后每股收益为0.12美元,2024年同期为0.09美元[41] - 2025年上半年加权平均流通股(稀释后)为21.187亿股,2024年同期为19.198亿股[41] - 2025年上半年反稀释股份排除数量为5.6523亿股,2024年同期为5.7243亿股[41] 股权结构 - 公司A类普通股流通股为1625.1978万股,B类普通股流通股为4669.6493万股[9]
3D Systems(DDD) - 2025 Q2 - Quarterly Results
2025-08-12 04:30
EXHIBIT 99.1 3D Systems Reports Second Quarter 2025 Financial Results ROCK HILL, South Carolina - August 11, 2025 - 3D Systems Corporation (NYSE:DDD) announced today its financial results for the second quarter ended June 30, 2025. Summary of Financial Results (Unaudited) Three Months Ended Six Months Ended (in millions, except per share data) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Revenue $ 94.8 $ 113.3 $ 189.4 $ 216.2 Gross profit 36.2 47.1 68.8 88.0 Gross profit margin 38.1% 41.6% 36.4% ...
Guardian Pharmacy Services, Inc.(GRDN) - 2025 Q2 - Quarterly Report
2025-08-12 04:26
Table of Contents Commission File Number: 001-42284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Guardian Pharmacy Services, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-3627 ...
Green Plains(GPRE) - 2025 Q2 - Quarterly Report
2025-08-12 04:26
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______ to ______ Commission File Number 001-32924 GREEN PLAINS INC. (Exact name of registrant as specified in its cha ...
Apartment Investment and Management pany(AIV) - 2025 Q2 - Quarterly Report
2025-08-12 04:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-13232 (Apartment Investment and Management Company) Commission File Number: 0-56223 (Aimco OP L.P.) Apartment Investment and Manag ...
Palisade Bio(PALI) - 2025 Q2 - Quarterly Report
2025-08-12 04:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33672 PALISADE BIO, INC. (Exact name of registrant as specified in its charter) | | Trading | | | --- | --- | --- | | Title of e ...
Denali(DNLI) - 2025 Q2 - Quarterly Report
2025-08-12 04:25
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38311 Denali Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...